Skip to main content

NanoString to Unveil New Platforms and Showcase Spatial Biology Research at 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

Live webcast of Spatial Multiomic Symposium on Monday, June 6, from noon to 4 pm EDT

Data from twenty scientific studies highlight the use of NanoString’s spatial biology platforms

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced plans to commercially unveil the CosMx™ Spatial Molecular Imager (SMI) and its new spatial informatics portal during a Spatial Multiomic Symposium, which will be held on Monday, June 6 from noon to 4:00 pm EDT. The event will be live-streamed and held in person, and details can be found here: Spatial Multiomics Symposium - NanoString. In addition, scientists will present 20 studies demonstrating the power of NanoString spatial biology platforms during the scientific portion of the AGBT General Meeting.

CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 100 protein analytes within morphologically intact whole tissue sections. The technology combines the power of high-plex profiling with high-resolution imaging, allowing researchers to visualize and quantify gene and protein expression at single cell and subcellular resolutions within both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. CosMx SMI serves scientists across the continuum of research using a tunable workflow that can prioritize either unbiased whole-slide imaging at high-plex for discovery or high-throughput biology-driven analysis for translation.

NanoString is dedicated to developing spatial biology solutions for any scale of research. The GeoMx DSP is the leading platform for measuring whole transcriptome at high-throughput in multi-cellular functional regions and the CosMx SMI extends capability to single cell and subcellular resolution across the entire tissue section. Together, GeoMx DSP and CosMx SMI technologies provide unprecedented scientific power for novel spatial discoveries.

Spatial biology experiments are data-intensive, creating up to 1 terabyte of data per sample. NanoString is developing a new cloud-based spatial informatics portal that will provide researchers with a scalable solution to store large GeoMx and CosMx datasets, reduce compute times, and enable secure data sharing and collaboration across institutes.

The Spatial Multiomic Symposium will showcase the application of these powerful tools to resolve biological heterogeneity. Attendees will learn about the latest innovations and will have the opportunity to hear how leading experts are applying these technologies to make novel discoveries in immunology, infectious diseases, oncology and neuroscience.

“We believe spatial biology is the next revolution in life sciences, and we’re honored to bring together experts to showcase cutting-edge spatial technologies and techniques,” said Brad Gray, president and CEO, NanoString Technologies. “The volume and quality of NanoString-driven science being presented at AGBT 2022 is a testament to the power of our spatial biology ecosystem.”

The Spatial Multiomic Summit Agenda: Speakers and Scientific Presentations

  • Keynote: Spatial gene expression changes in human skin biology induced from spaceflight: Christopher Mason, Ph.D., Professor; Director, WorldQuant Initiative for Quantitative Prediction; Physiology and Biophysics, Weill Cornell Medicine
  • Spatially resolved, single cell atlas of human pancreatic islets of Langerhans in type 2 diabetic and healthy controls: Grant Kolar, M.D., Ph.D., Assistant Research Professor Director, Research Microscopy and Histology Core, St. Louis University
  • Deep spatiotemporal insights into COVID-19: a multi-organ study: Arutha Kulasinghe, Ph.D., National Health and Medical Research Council Research Fellow, The University of Queensland
  • Spatial reconstruction of joint inflammation in rheumatoid arthritis: Kevin Wei, M.D., Ph.D., Assistant Professor of Medicine, Brigham and Women’s Hospital
  • Spatially resolved Alzheimer’s disease in mouse model: Miranda Orr, Ph.D., Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine

To learn more and register for the event, please visit: Spatial Multiomics Symposium - NanoString

At AGBT 2022, 20 posters and oral presentations will showcase unique biological insights generated using NanoString’s spatial platforms. These abstracts include studies exploring spatial biology using the GeoMx DSP and the CosMx SMI platforms.

“As single-cell resolution spatial transcriptomics and proteomics pioneer the next frontier in spatial biology, our understanding of fundamental processes in biology will deepen and perhaps pave the way for next-generation diagnostic and pathology tools,” said Joe Beechem, chief scientific officer, NanoString Technologies. “The CosMx SMI system is ideal for deeper single-cell exploration downstream of whole transcriptome analysis carried out on GeoMx DSP and the two systems can essentially be used for complementary experiments on a set of samples.”

Several studies and presentations that feature NanoString’s spatial biology platforms are highlighted below.

Oral Presentations

Multicellular spatial neighborhoods in pancreatic cancer remodeled by neoadjuvant treatment will be presented by Will Hwang, M.D., Ph.D., radiation oncologist and research fellow, Massachusetts General Hospital Cancer Center/Harvard Medical School, on June 6 from 6:05-6:25 pm. Discover the unique interaction between malignant cells and nerves/microenvironment during the response to treatment for PDAC, using GeoMx DSP and CosMx SMI platforms.

Building a spatial single-cell multi-omics atlas and cellular interactome for skin cancer will be presented by Quan Nguyen, Ph.D., the University of Queensland on June 7 from 7:50-8:10 pm. Learn how CosMx profiling enables spatial interactome analysis that provides new insights in the development of skin cancer. This will be a comparison of six spatial platforms.

High-plex (> 1000), multi-omic (RNA plus protein), spatial molecular imaging with sub-cellular resolution in FFPE tissue, will be presented by Joe Beechem, Ph.D., chief scientific officer, NanoString Technologies. Concurrent sessions will run from 8:50-9:10 pm on June 8. Learn how high-plex multi-omic (RNA and protein) targets detected in FFPE samples using CosMx SMI, at subcellular and single-cell resolution in >1 million cells from a single slide uncovers novel biological insights that were previously lost in space.

Scientific Posters

Poster: Spatial characterization of the tumor microenvironment in pancreatic cancer with whole transcriptome profiling and high plex single-cell imaging.

David Ting, M.D., Chief Medical Information Officer, Mass General Physicians Organization, Co-Director, MGH Center for Innovation in Digital HealthCare, Assistant Professor, Harvard Medical School

See the origin of exosomes in tumor microenvironments and the effect of their migrations in pancreatic cancer tissues using the CosMx SMI platform.

Poster: Characterization of human brain organoids with single-cell resolution and molecular specificity

Florent Ginhoux, Ph.D., Senior Principal Investigator · Singapore Immunology Network, Agency for Science, Technology and Research

Learn how CosMx single-cell imager enables unique analyses and understanding of human brain organoid cells in space.

Poster: Spatially-mapped quantitative single-cell characterization of PD-L1-related RNA microenvironments in triple-negative breast cancer

Aubrey Thompson, Ph.D., Co-director of the Mayo Clinic Breast Cancer Translational Genomics Program

Learn how CosMx and GeoMx spatial platforms generate consistent data for clinical biomarkers of response to IO therapy.

Poster: Spatial Single Cell characterization of SIV reservoirs in lymphoid tissues and B cell follicles in rhesus macaques

Jake Estes, Ph.D., Professor, VGTI-Vaccine and Gene Therapy Institute; Chief, Division of Pathobiology & Immunology, Oregon National Primate Research Center

Uncover how subcellular localization of SIV RNAs in NHP revealed by CosMx and response to drug targets in infected-cell microenvironments studied using GeoMx DSP provides novel analysis tools for vaccine development.

Poster: High-plex spatial single cell in situ analysis of lung SARS-CoV-2

Arutha Kulasinghe, Ph.D., NHMRC Research Fellow, Queensland University of Technology

Discover the consistent insights in COVID biology and biomarkers uncovered by the CosMx SMI and GeoMx DSP platforms at different scales.

To see the complete list of 2022 AGBT posters and learn more about the data presented on the GeoMx DSP and CosMx SMI platforms, visit NanoString’s AGBT event page.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,300 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 120 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our products and the anticipated launch of new products and technology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contacts

Doug Farrell

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.